Related Experiment Video
Updated: Feb 17, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
10.2K
Current treatment algorithm for the management of lower-risk MDS
1Department of Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany.
Hematology. American Society of Hematology. Education Program
|December 10, 2017
Summary
Lower risk myelodysplastic syndromes (MDS) treatment focuses on supportive care and reducing transfusions. Erythropoiesis-stimulating agents and novel therapies offer options for transfusion independence in MDS patients.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Lower risk myelodysplastic syndromes (MDS) present ongoing treatment challenges.
- Supportive care is crucial, with evolving strategies to minimize red blood cell transfusions.
Purpose of the Study:
- To review current and emerging treatment options for lower-risk MDS.
- To discuss strategies for achieving transfusion independence and managing specific complications.
Main Methods:
- Review of therapeutic approaches for lower-risk MDS.
- Analysis of treatment efficacy for erythropoiesis-stimulating agents, lenalidomide, immunosuppressive agents, and thrombopoietin receptor analogues.
- Consideration of allogeneic stem cell transplantation for high-risk progression.
Main Results:
- Erythropoiesis-stimulating agents are effective for transfusion independence in eligible non-del(5q) MDS patients.
- Lenalidomide shows long-term benefits for del(5q) MDS and can lead to sustained transfusion independence.
- Experimental agents like immunosuppressants and TGF-β inhibitors offer alternatives with reasonable response rates.
Conclusions:
- Supportive care remains central to managing lower-risk MDS.
- Multiple therapeutic avenues exist to improve transfusion independence and quality of life.
- Allogeneic stem cell transplantation is reserved for high-risk progression or treatment failure.
